|Bid||27.35 x 10700|
|Ask||27.40 x 2100|
|Day's range||27.40 - 27.78|
|52-week range||10.45 - 27.82|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||0.30 (1.67%)|
|1y target est||25.50|
The head of Sirtex Medical says he is not surprised US suitor Varian Medical offered a 49 per cent share price premium in its $1.6 billion takeover offer for the Australian cancer treatment developer . Sirtex CEO Andrew McLean says he was "not at all" surprised by Varian's offer, which at $28 for each Sirtex share represents a 49 per cent mark-up on the January 29 closing price of $18.83, and a 60 per cent premium to the average price over January. "Sirtex is a wonderful business with strong prospects," Mr McLean said on Wednesday.
Shares in liver cancer treatment developer Sirtex Medical have soared, gaining almost 50 per cent after resuming trading on Wednesday following news that US cancer care firm Varian has agreed to pay $1.6 ...
Australian-based liver cancer treatment developer Sirtex Medical has agreed to a $1.6 billion takeover offer from US company Varian. Sirtex distributes a radiation therapy to more than 1,090 hospitals in over 40 countries, and currently has a market value of $1.05 billion. Varian, which is listed on the New York Stock Exchange with a market value of $US11.8 billion, is based in California and develops radiotherapy and screening technology to treat cancer.
Varian Medical Systems Inc. agreed to buy Australia’s Sirtex Medical Ltd. for about A$1.6 billion ($1.3 billion) in a bid by the U.S. company to add radiation medicine to its portfolio for cancer treatments....
Shares in Sirtex Medical have been placed in a trading halt ahead of what the cancer treatment specialist called a "potential material corporate transaction". The liver cancer treatment developer, which booked a $26.3 million loss in 2016/17 after writedowns and failed clinical trials, this month said it expects underlying first-half earnings of $34 million - a 16 per cent improvement on the previous first half.
Sirtex Medical shares have surged after the liver cancer treatment specialist flagged improved first-half earnings and a turnaround in second-half sales. Sales of the company's SIR-Spheres microspheres - a product used to deliver medication to cancer sites inside the body - were flat in the first half but Sirtex CEO Andrew McLean, who took up his role in May, said the company expects higher sales in the second half of 2017/18.
The Sirtex Medical Limited (ASX:SRX) share price jumped 13% to a 52-week high today, following an earnings update.
IMF Bentham Ltd (ASX:IMF) has made a name for itself trying claw cash back from companies for investors. But should you invest in IMF?
Liver cancer treatments group Sirtex Medical says dosage sales in the first three months of the current financial year have been flat and sales revenue is down because of adverse currency movements, but profit is improving. Chief executive Andrew McClean has told shareholders that the first quarter is showing "some early favourable results" from the company's efforts to improve efficiency and productivity. Sirtex's main product is a medical device called SIR-Spheres Y-90 resin microspheres, to treat liver cancer.
Liver cancer treatments group Sirtex Medical says revenue for the first quarter of 2017/18 has dipped as a result of flat unit sales and adverse currency movements. Sirtex CEO Andrew McClean has told the company's annual general meeting that the first quarter is showing "some early favourable results", dose sales of cancer treatments are flat on the corresponding previous quarter and sales revenue is down about five per cent after currency effects.
WOBURN, Mass.--(BUSINESSWIRE)-- Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX.AX - News), a leading manufacturer of targeted liver cancer therapies, today announced the Combined FOXFIRE Analysis that evaluated SIR-Spheres Y-90 resin microspheres in combination with chemotherapy in patients with mCRC did not improve overall survival compared to chemotherapy alone. The Combined FOXFIRE Analysis is comprised of data from the SIRFLOX study first presented in 2015 and data from two new studies – FOXFIRE and FOXFIRE-Global.